APLS Apellis Pharmaceuticals
- 42.300
- -1.600-3.64%
- 42.300
- 0.0000.00%
Apellis Pharmaceuticals News
Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $60
HC Wainwright & Co. : Apellis Pharmaceuticals (APLS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $92.00.
Apellis Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price Target
Apellis Pharmaceuticals Holds Steady Amid Market Challenges and Competitive Pressures
UBS Adjusts Price Target on Apellis Pharmaceuticals to $85 From $89, Maintains Buy Rating
UBS Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $85
Buy Rating Affirmed for Apellis Pharmaceuticals Amid Robust Sales and Market Expansion Potential
Optimistic Outlook: Buy Rating on Apellis Pharmaceuticals Amid Strong Syfovre Sales and Upcoming VALIANT Trial Results
Apellis Pharmaceuticals Analyst Ratings
Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $50 From $57, Maintains Neutral Rating
Buy Rating Reaffirmed for Apellis Pharmaceuticals Amid Strong Syfovre Sales and Robust Financial Outlook
Mizuho Bank: Maintaining the Apellis Pharmaceuticals (APLS.US) rating, adjusted from neutral to neutral, and the target price was adjusted from $60.00 to $52.00.
Mizuho Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $52
Apellis Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth Potential
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX) and Healthcare Services (HCSG)
Impact of Izervay's Growth on Apellis Pharmaceuticals: Maintaining a Hold Rating Amidst Rising Competition
Apellis Pharmaceuticals Analyst Ratings
Maintaining Market Dominance: Strong Buy Rating on Apellis Pharmaceuticals With a Target Price of $85
Analysis
Price Target
No Data
